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GLUT2 is mainly expressed in the liver, -cells of the
pancreas, and the basolateral membrane of kidney prox-
imal tubules and plays an important role in glucose
homeostasis in living organisms. The transcription of
the GLUT2 gene is known to be upregulated in the liver
during postprandial hyperglycemic states or in type 2
diabetes. However, a molecular mechanism by which
glucose activates GLUT2 gene expression is not known.
In this study, we report evidence that sterol response
element–binding protein (SREBP)-1c plays a key role in
glucose-stimulated GLUT2 gene expression. The GLUT2
promoter reporter is activated by SREBP-1c, and the
activation is inhibited by a dominant-negative form of
SREBP-1c (SREBP-1c DN). Adenoviral expression of
SREBP-1c DN suppressed glucose-stimulated GLUT2
mRNA level in primary hepatocytes. An electrophoretic
mobility shift assay and mutational analysis of the
GLUT2 promoter revealed that SREBP-1c binds to the
84/76 region of the GLUT2 promoter. Chromatin im-
munoprecipitation revealed that the binding of SREBP-1c
to the 84/76 region was increased by glucose concen-
tration in a dose-dependent manner. These results indi-
cate that SREBP-1c mediates glucose-stimulated
GLUT2 gene expression in hepatocytes. Diabetes 54:
1684–1691, 2005
A dipocyte determination and differentiation–de-pendent factor 1 (ADD1)/sterol response ele-ment binding protein (SREBP)-1c is a trans-acting factor that regulates transcription of
many genes involved in cholesterol and fatty acid synthe-
sis (1–6). To date, three isoforms of SREBP have been
identified. SREBP-1a and -1c are derived from a single
gene and use different transcription initiation sites (7).
SREBP-2 is transcribed from a separate gene (8) and
shows 50% sequence homology to the SREBP-1c isoform.
SREBP-2 plays a critical role in the regulation of genes of
cholesterol biosynthesis, whereas SREBP-1c regulates li-
pogenesis genes in liver (9).
The relative contribution of insulin (10–14) or glucose
(15–17) to the regulation of specific genes is known to be
different. In nonfasted mice, the level of SREBP-1c tran-
scripts in the liver is considerably more abundant than the
SREBP-1a transcripts (3). Fasting decreases the amount of
SREBP-1c transcripts by 60%, and refeeding increases the
level by 3.8-fold (3). In contrast, the fasting/refeeding
protocol causes only minor changes in the amount of
SREBP-1a transcripts (18). In insulin-resistant animals,
such as ob/ob mice, where insulin signaling is known to be
impaired (19), or in other insulin signaling system knock-
out animals (20), overexpression of SREBP-1c in the liver
was reported (12). These reports suggested that SREBP-1c
induction could also occur by glucose.
The facilitative GLUTs are a group of highly related
membrane proteins that share significant sequence homol-
ogy between isoforms (21). GLUT2 is known to transport
glucose across the hepatic plasma membrane in a bi-
directional manner (22,23). GLUT2 was upregulated by
glucose, like pyruvate kinase and fatty acid synthase (24).
In diabetic states, GLUT2 in the liver and basolateral
membrane of renal proximal tubules is known to be
upregulated, indicating that hyperglycemia may play a
positive role in its gene regulation (25). And in streptozo-
tocin-induced diabetic rats, where insulin was depleted in
vivo (10), SREBP-1c expression was increased in liver.
These data lead us to postulate that GLUT2 upregulation in
the liver could be due to the activation of the gene by
SREBP-1c.
From this background, we have attempted to identify
the SREBP-1c response element (SRE) in the promoter
region of GLUT2 and demonstrate that glucose increases
the binding of SREBP-1c on the GLUT2 promoter, result-
ing in the activation of GLUT2 transcription.
RESEARCH DESIGN AND METHODS
All the reagents for cell culture, such as media, fetal bovine serum (FBS),
antibiotics, and LipofectAMINE PLUS, were purchased from Life Technolo-
gies. [-32P]ATP, [-32P]dCTP, Rediprime labeling kits, and a rapid hybridiza-
tion solution were purchased from Amersham Biosciences.
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Preparation of recombinant SREBP-1 and SREBP-1 antibody. Recombi-
nant SREBP-1 was prepared as described (5). Briefly, recombinant human
SREBP-1 were expressed in Escherichia coli BL21(DE3)pLysS. SREBP-1 ex-
pression vector pET-SREBP-1a was generated by inserting the cDNA frag-
ments from pCSA10 between the EcoRI and SalI sites of pET-21a (Novagen)
and used for transformation. The recombinant SREBP-1 was induced for 4 h
with 1 mmol/l isopropyl--D-thiogalactopyranoside. The recombinant proteins
containing NH2-terminal T7 and COOH-terminal polyhistidine (His6) tag were
purified to homogeneity by Ni-NTA-agarose (Qiagen) chromatography. The
purity and concentration of the recombinant proteins were verified by
SDS–polyacrylamide gel electorphoresis followed by Coomassie Brilliant Blue
staining.
Polyclonal antibody against the recombinant SREBP-1 was prepared by
standard protocol, which was prepared as described previously (26). One
milligram of recombinant SREBP-1 protein was suspended in 1 ml of PBS and
emulsified with 1 mmol/l of Freund’s complete adjuvant (Sigma, St. Louis,
MO). The emulsified solution was subcutaneously injected into the back of
New Zealand white rabbit. After 3 weeks, the booster injection was adminis-
tered with the same amount and volume of antigen emulsified with Freund’s
incomplete adjuvant (Sigma). The booster injections were repeated three
times in 3-week intervals. At 10 days after the final booster injection, the blood
was collected by the heart puncture under the anesthesia using 50 mg/kg of
ketamine hydrochloride and 5 mg/kg of xylazine hydrochloride. The collected
blood was incubated in 37°C for 1 h to complete coagulation, and the serum
was isolated after centrifugation at 10,000g for 10 min.
Animals and treatments. Male ICR mice (7 weeks of age) were fed a fat-free,
high-carbohydrate diet containing 82% (wt/wt) carbohydrates (74% starch and
8% sucrose), 18% (wt/wt) casein, 1% vitamin mix, and 4% (wt/wt) mineral mix
and then fasted for 24 h. All the materials for the diet were purchased from
Harlem Teklad (Madison, WI).
Primary hepatocytes preparation from mouse liver. Hepatocytes were
isolated from a male ICR mouse (7 weeks of age) by the collagenase perfusion
method (27). Dissociation into individual hepatocytes was performed in
Dulbecco’s modified Eagles’ medium (DMEM) (Invitrogen) containing 10%
heat-inactivated FBS, 100 nmol/l insulin, 10 mol/l dexamethasone, 25 mmol/l
glucose, 100 unit/ml penicillin G, and 100 g/ml streptomycin. For each
hepatocyte preparation, cell viability was estimated by the exclusion of trypan
blue.
Isolation of total RNA and Northern blot analysis. Total cellular RNA was
extracted from primary hepatocytes using the TRIzol reagent method (Life
Technologies, Rockville, MD) (28) and prepared according to the manufac-
turer’s protocol. Twenty micrograms of each sample was denatured and
subjected to electrophoresis in a 0.9% denaturing formaldehyde-agarose gel
and transferred to a nylon membrane. The membranes were hybridized with
the probe for 3 h at 65°C with Rapid-Hybrid buffer (Amersham Biosciences).
After hybridization, the membrane was washed twice with a high-salt washing
buffer (0.1% SDS, 2  SSC [sodium chloride/sodium citrate]) at room temper-
ature for 30 min, followed by a low-salt washing buffer (0.1% SDS, 0.2  SSC)
at 65°C for 15 min. The membrane was exposed to Kodak BioMax film using
an intensifying screen at 70°C.
RNA preparation and RT-PCR. Total RNA was isolated from primary
hepatocytes using TRIzol reagent according to the manufacturer’s protocol
(Life Technologies). For RT-PCR, the first strand of cDNA was synthesized
from 3 l of total RNA using random hexamers and Superscript II reverse
transcriptase (Life Technologies). One microliter of the reverse transcription
reaction mixture was amplified with primers specific for GLUT2 and glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) in a total volume of 50 l.
Linearity of the PCR was tested with amplification cycles between 25 and 30.
According to the test amplification profile, samples were amplified at 94°C for
30 s, 56°C for 30 s, and 72°C for 28 s. GAPDH was used as an internal control
for quality and quantity of RNA. The PCR primers used were as follows:
GLUT2 sense, 5-GGCTAATTTCAGGACTGGTT-3; GLUT2 antisense, 5-TTTC
TTTGCCCTGACTTCCT-3; GAPDH sense, 5-ACCACAGTCCATGCCATCAC-
3; and GAPDH antisense, 5-TCCACCACCCTGTTGCTGTA-3.
Quantitative real-time PCR. Primers for GLUT2, SREBP-1a, SREBP-1c,
SREBP-2, and -tubulin genes were designed using MacVector software
(Accelrys). The PCR mixture was performed in 10 l (final volume) in glass
capillary tubes (Roche Diagnostics). The PCR mixture contained 1 l of 100 ng
cDNA template, 1 l of a commercial ready-to-use mixture of LightCycler-
DNA Fast Start master hybridization probes (Roche Diagnostics), 5 mmol/l
MgCl2 (final concentration), and primers and probes at final concentrations of
5 and 1 mol/l, respectively. Real-time PCR was carried out using a LightCycler
instrument (Roche Diagnostics). The conditions for thermal cycling were as
follows: initial denaturation for 10 min, followed by 40 amplification cycles at
95°C for 10 s, 58°C for 5 s, and 72°C for 14 s. Fluorescence was measured at
640 nm (F2 channel) at the end of each annealing phase. The amplification was
followed by a melting program, which started at 45°C for 15 s and then
increased to 95°C by 0.1°C/s, with the fluorescence signal continuously
monitored online. Primers and probes were as follows: GLUT2 sense, 5-
GGCTAATTTCAGGACTGGTT-3; GLUT2 antisense, 5-TTTCTTTGCCCTG
ACTTCCT-3; SREBP-1a sense, 5-GGCCGAGATGTGCGAACT-3; SREBP-1a
antisense, 5-TTGTTGATGAGCTGGAGCATGT-3; SREBP-1c sense, 5-GGAG
CCATGGATTGCACATT-3; SREBP-1c antisense, 5-GGCCCGGGAAGTCACT
GT-3; SREBP-2 sense, 5-GCGTTCTGGAGACCATGGA-3; SREBP-2 anti-
sense, 5-CACAAGTTGCTCTGAAAACAAATCA-3; -tubulin sense, 5-CTCG
CATCCACTTCCCTC-3; and -tubulin antisense, 5-ATGCCCTCACCCACGTA
C-3.
Construction of GLUT2 promoter luciferase plasmids. The GLUT2 pro-
moter fragments of 1,112/1 bp were PCR amplified from mouse genomic
DNA and subcloned into a pGLM vector and mutated at the E-boxes upstream
of the multiple cloning site of the pGL3 basic vector. 5 serial deletions of
mouse GLUT2 promoter reporter were constructed by amplifying the regions
of 891/1, 389/1, 286/1, 116/1, and 57/1 bp, respectively. SRE
mutant construct pmGLUT2d-389m was generated from pmGLUT2d-389 with
the mutagenic oligonuleotides (30 mer) using plaque-forming unit polymerase.
The sequences of all constructs were confirmed using a T7 sequencing kit
(Amersham Biosciences). All transfection plasmids were prepared with the
Qiagen Plasmid Midi Kit.
Transient transfection assay. Alexander cell lines (American Type Culture
Collection number CRL-8024), which are human epithelial hepatoma cell lines,
were plated at a density of 2  105 cells/35-mm dish. On the following day, 0.5
g of each construct of the GLUT2 promoter, 0.1 g of pCMV–-galactosidase,
with or without 0.1 g of SREBP-1c, and 0.5 g of dominant-negative form of
SREBP-1c (SREBP-1c DN) expression vector were mixed. Transient transfec-
tion and luciferase assays were performed as described previously (29). Total
protein concentrations of the lysates were determined by the Bradford
method (30). Luciferase activities were normalized by the amount of total
protein. Each transfection was performed in triplicate and repeated three to
five times.
Electrophoretic mobility shift assay. The oligonucleotide probes GLUT2-
SRE and GLUT2-SREm (GLUT2-SRE mutant) were labeled as described
previously (31). Ten picomoles of the single-stranded sense oligonucleotide
were labeled with [-32P]ATP using T4 polynucleotide kinase and annealed
with 50 pmol of unlabeled antisense oligonucleotides. For competition assay,
unlabeled oligonucleotides (100-fold molar excess) were added to the reaction
mixture. The oligonucleotide sequences used in electrophoretic mobility
shift assay (EMSA) were as follows: GLUT2-SRE sense, 5-CCAGGTAGAG
TGAGCACTCT-3; GLUT2-SRE antisense, 5-AGAGTGCTCACTCTACCTGG-
3; GLUT2-SREm sense, 5-CCAGGTAGAGaacGCACTCT-3; GLUT2-SREm
antisense, 5-AGAGTGCgttCTCTACCTGG-3; mLDLR-SRE sense, 5-TTGAAA
ATCACCCCATTGCAGACTCCTCCCCGGC-3; and mLDLR-SRE antisense,
5-GCCGGGGAGGAGTCTGCAATGGGGTGATTTTCAA-3. Mutated bases are
represented in bold.
Preparation of recombinant adenovirus. Recombinant adenovirus encod-
ing SREBP-1c or SREBP-1c DN was prepared according to Choi et al. (32).
Briefly, the respective cDNAs were cloned into pAd-YC2 (5 g) and trans-
fected into 293 cells with a rescue vector, pJM17 (5 g), which is necessary for
homologous recombination of the recombinant adenovirus. After 12–15 days,
recombinants were screened by PCR using upstream primers derived from the
cytomegalovirus promoter and downstream primers from the bGHp(A) se-
quence. The recombinants were amplified in 293 cells and purified and iso-
lated using CsCl2 (Sigma). The recombinant adenoviruses were collected and
desalted, and titers were determined by the measurement of plaque counts.
Treatment of recombinant adenovirus. Null, adenovirus, or adenovirus
containing SREBP-1 or SREBP-1c DN were treated according to the method
described by Kim et al. (29). The primary hepatocytes were incubated for 2 h
with an adenovirus containing DMEM at a titer of 5 pfu per cell for 2 h at 37°C.
Culture medium was then replaced by DMEM supplemented with 10% FBS.
The infected cells were harvested for RNA isolation 24 h after viral infection.
Chromatin immunoprecipitation assay. The chromatin immunoprecipita-
tion (ChIP) assay protocol was adapted from methods described by Duong et
al. (32). The primary hepatocytes were fasted in fasting medium composed of
2 mmol/l glutamine, 1 mmol/l sodium pyruvate, 10 mmol/l lactate, 10 nmol/l
dexamethasone, and 2% FBS for 16 h. The medium was then changed to one
containing 25 mmol/l glucose and/or 100 nmol/l insulin for 24 h. Cells were
washed with ice-cold PBS and cross-linked with 5% formaldehyde in serum-
free DMEM for 5 min. The cells were homogenized, pelleted by centrifugation
at 2,000 rpm for 4 min at 4°C, and resuspended in SDS lysis buffer (1% SDS, 10
mmol/l EDTA, 50 mmol/l Tris-HCl, pH 8.0). The lysate was sonicated on ice for
3 min at a setting of cycle 0.5, amplitude 30, and sheared to between 100 and
600 bps. To provide a positive control (input) for each condition, one
undiluted aliquot was retained for further processing in parallel with all the
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other samples at the reversal of the cross-linking step. To reduce nonspecific
background, each chromatin sample (1 ml) was precleared with 60 l of
protein A/G agarose (Santa Cruz Biotech), supplemented with 200 g/ml
sonicated salmon sperm DNA (Stratagene, La Jolla, CA), and the beads were
pelleted. Chromatin complexes in the supernatant were immunoprecipitated
overnight at 4°C using either 30 g of SREBP-1 antibody or without antibody.
Immune complexes were collected with 60 l of protein A/G agarose including
200 g/ml of salmon sperm DNA (Stratagene). Promoter-specific PCR GLUT2
promoter primers were as follows: sense, 5-CCATCAATACTCAGCTTCTG-3;
antisense, 5-TGTGTGTGTGTGGAATTGTC-3.
Statistical analysis. All transfection studies were performed in three to five
separate experiments, where triplicate dishes were transfected. The data were
represented as a mean 	 SD. Statistical significance was determined by inde-
pendent two-sample t tests or paired t tests between two groups of datasets.
RESULTS
Effect of glucose and insulin on the mRNA level of
GLUT2 and SREBPs in primary cultured hepatocytes.
To observe the effects of glucose and/or insulin on the ex-
pression of SREBP-1 and GLUT2, we treated primary cul-
tured hepatocytes with high glucose (25 mmol/l), insulin
(100 nmol/l), or both. Northern blot and real-time PCR
analyses showed that treatment with insulin (100 nmol/l)
or glucose (25 mmol/l) increased the SREBP-1 mRNA level
(Fig. 1A and B). However, GLUT2 expression was not
affected by insulin alone but was stimulated by addition of
high glucose (Fig. 1B, *P 
 0.001 for the untreated vs.
glucose-treated group). These data suggest that glucose is
a major determinant in GLUT2 gene upregulation. Real-
time PCR of the SREBP-1 isoform revealed that insulin or
glucose treatment activated SREBP-1c expression (Fig.
1C), whereas SREBP-1a and SREBP-2 expressions were
not affected by both insulin and glucose (Fig. 1D and E).
Insulin and glucose increased SREBP-1c mRNA level by
seven- and fourfold, respectively (Fig. 1C, *P 
 0.005 for
the untreated vs. insulin-treated group and #P 
 0.05 for
the untreated vs. glucose-treated group). Insulin and glu-
cose showed additive effect (Fig. 1C, †P 
 0.001 for the
untreated vs. glucose/insulin-treated group) in activating
SREBP-1c expression.
Effect of SREBP isoforms on GLUT2 promoter re-
porter activity in the Alexander cell lines. As shown in
Fig. 2, SREBP-1c activated GLUT2 promoter reporter by
5.2-fold (*P 
 0.001 for the untransfected vs. SREBP-1c
group), whereas SREBP-2 activated the promoter by 2.4-
fold (#P 
 0.05 for the untransfected vs. SREBP-2 group),
suggesting that SREBP-1c acts as more potent activator of
GLUT2 promoter than SREBP-2 isoform.
Localization and characterization of SRE in the
GLUT2 promoter. To identify a putative SRE in the
mouse GLUT2 promoter, serial deletion constructs of the
5-flanking region of the GLUT2 promoter were prepared
(from 1,112, 890, 389, 283, 166, and 57 to 1,
shown in Fig. 3A), and their responsiveness to SREBP-1c
in Alexander cell lines was observed. The SREBP-1c effect
was decreased by deleting the bases down to 57
(pmGT2d-57), indicating that a putative SRE could be
located between the 166- and 57-bp regions (Fig. 3B,
*P 
 0.005 for the 166- vs. 57-bp deletion construct). A
consensus sequence search suggested that a highly con-
served SREBP-1 binding site could be present in this
FIG. 1. Effect of glucose and insulin on
the mRNA level of GLUT2 and SREBPs
in primary cultured hepatocytes. A:
Hepatocytes isolated from mice were
plated for 5 h and cultured for a further
16 h in the presence or absence of insu-
lin (100 nmol/l) and glucose (25 mmol/
l). Total RNA was extracted from each
treatment group as described in RE-
SEARCH DESIGN AND METHODS. B–E: Quanti-
fication of hepatic mRNA for GLUT2,
SREBP-1c, SREBP-1a, and SREBP-2. To-
tal RNA (3 g) used in reverse tran-
scription experiments was subjected
to real-time PCR. The data were quan-
tified as described in RESEARCH DESIGN
AND METHODS. All mRNA levels were nor-
malized to that of -tubulin. The results
are the means  SD of three indepen-
dent experiments with triplicate mea-
surements. B: *P < 0.001 for the un-
treated vs. glucose-treated group; C:
*P < 0.005 for the untreated vs. insulin-
treated group, #P < 0.05 for the un-
treated vs. glucose-treated group, and
†P< 0.001 for the untreated vs. glucose/
insulin-treated group.
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region. To identify an SRE in this region, EMSA was
performed. Recombinant SREBP-1 (5) bound well with the
probe in a dose-dependent manner up to 60 ng (Fig. 3C).
The specificity of the SREBP-1c binding was further
confirmed by the SRE consensus sequence from the LDL
receptor (LDLR) promoter (33) (Fig. 3D, lane 3). Mutation
introduced at 78/76 (TGA 3 aac, SRE mutant in Fig.
3D) resulted in a loss of SREBP-1 binding (Fig. 3D, lanes 5
and 6). The aac mutant lost its ability to compete the
binding of SREBP-1 to the GLUT2-SRE consensus se-
quence (Fig. 3D, lane 4). Transfection of the putative
GLUT2-SRE mutant promoter construct (pmGT2d-389m)
lost its responsiveness to SREBP-1c (Fig. 3E, f). These
results indicate that the 84/76 region acts as a possible
SRE regulating GLUT2 gene expression.
Effect of a GLUT2-SRE mutation on the glucose-
stimulated GLUT2 promoter reporter activity. To
confirm that the 84/76 region is a functional SRE in the
GLUT2 promoter, the GLUT2 promoter reporters (pmGT2d-
389 and pmGT2d-389m) were transfected to Alexander cell
lines maintained at concentrations of 5 and 25 mmol/l
glucose. The wild-type promoter reporter activity was
increased by glucose in a dose-dependent manner (Fig. 4A,
*P 
 0.05 for the 0 vs. 25 mmol/l glucose–treated group).
The GLUT2-SRE mutant construct (pmGT22d-389m) showed
decreased promoter reporter activity when compared with
wild-type promoter (pmGT22d-389, #P 
 0.05 for the wild-
versus mutant-type at 25 mmol/l glucose). Again, the acti-
vation of the promoter construct by glucose (25 mmol/l)
was suppressed by cotransfection of the SREBP-1c DN
(Fig. 4B, #P
 0.05 for the 25 mmol/l vs. 25 mmol/l glucose
plus SREBP-1c DN group), indicating that GLUT2 pro-
moter activation by glucose is specifically mediated by
SREBP-1c.
Glucose-stimulation of GLUT2 gene expression. To
observe the effect of glucose on GLUT2 and SREBP-1c
mRNA and protein level, primary hepatocytes were main-
tained at the indicated concentration of glucose. As shown
in Fig. 5A and B, GLUT2 mRNA and protein level increased
with glucose concentration in a dose-dependent manner.
To confirm that SREBP-1c mediates glucose-stimulated
GLUT2 expression, we transduced adenovirus containing
SREBP-1c DN into the primary hepatocytes in the pres-
ence or absence of glucose. Real-time PCR (Fig. 5C, upper
panel) and RT-PCR (Fig. 5C, lower panel) revealed that
GLUT2 expression was increased by glucose (25 mmol/l,
*P 
 0.005 for the untreated versus glucose-treated group),
and the stimulatory effect was suppressed by SREBP-1c
DN at the 25-mmol/l glucose concentration (#P 
 0.05 for
the glucose-treated versus glucose plus SREBP-1c DN
group). These data indicate that SREBP-1c is responsible
for the glucose-stimulated GLUT2 gene expression.
Glucose increased the binding of SREBP-1 to the
GLUT2 promoter in mouse primary cultured hepato-
cytes. To confirm the binding of SREBP-1 to the GLUT2
promoter by glucose in primary cultured hepatocytes, a
ChIP assay was performed. Chromosomal DNA from pri-
mary cultured hepatocytes was cross-linked using formal-
dehyde, and an antibody specific to SREBP-1 was used to
immunoprecipitate the chromatin fragment. A specific
region of the GLUT2 promoter (84/76) was amplified
by PCR. The binding of SREBP-1 to the GLUT2 promoter
was increased by glucose or glucose/insulin treatment
(Fig. 6A). The SREBP-1 binding to the GLUT2 promoter
was increased in a dose-dependent manner (Fig. 6B).
However, insulin did not affect the binding of SREBP-1 to
the putative SRE. These results indicate that glucose could
be one of the major factors in the binding of SREBP-1 to
the GLUT2 promoter, which may help explain the upregu-
lation of GLUT2 gene expression by glucose.
DISCUSSION
Recently, it has been suggested that the carbohydrate-
responsive element–binding protein (ChREBP) plays a
pivotal role in glucose-regulated gene expression (34),
whereas SREBP-1c acts as a major mediator of insulin
action in the lipogenic genes or in hepatic glucokinase
(35,36) and lipogenic gene expression (9,37). However,
glucose is required for lipogenic gene induction, where
insulin only plays a permissive role (15–17). In insulin-
resistant animals in which insulin signaling is impaired,
SREBP-1c expression in liver was shown to be increased.
For example, upregulation of SREBP-1c was reported in
the leptin-deficient obese ob/ob mice, lipoatrophic mice
overexpressing SREBP-1c in adipose tissue (19), insulin
receptor substrate-2 knockout mice (20), and rat pri-
mary hepatocytes infected with adenovirus-overexpress-
ing dominant-negative Akt (12). These observations sug-
gest that there may be additional mechanism of SREBP-1c
induction other than insulin signaling.
In this study, we demonstrated that glucose induced the
gene expression of SREBP-1c and GLUT2 in a dose-de-
pendent manner in the primary hepatocytes. Furthermore,
expression of GLUT2 gene is decreased by adenoviral
transduction of SREBP-1c DN in the mouse primary cul-
tured hepatocytes, indicating that glucose-stimulated
GLUT2 expression is mediated by SREBP-1c. We have
FIG. 2. Effect of SREBPs on GLUT2 promoter activity in the Alexander
cell lines. pmGT2-1112 promoter reporter was cotransfected with
SREBP-1c (100 ng) or SREBP-2 (100 ng) to Alexander cell lines, which
were plated at a density of 2  105 cells/35-mm dish. Transient
transfection, luciferase assays, and measurement of total protein
concentration of the lysates were performed as described in RESEARCH
DESIGN AND METHODS. Luciferase activities were normalized by the
amount of total protein. Each transfection was performed in triplicate
and repeated three to five times. *P < 0.001 for the untreated vs.
SREBP-1–transfected group; #P < 0.05 for the untreated vs. SREBP-2–
transfected group.
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identified a functional SRE in the mouse GLUT2 pro-
moter and demonstrated that SREBP-1c is the trans-
acting factor mediating glucose-stimulated GLUT2 gene
expression.
The question of how insulin-induced SREBP-1c did not
activate the GLUT2 gene expression, but glucose-induced
SREBP-1c increased GLUT2 mRNA level is not currently
understood. As shown in Fig. 6A, SREBP-1c induced
by insulin did not bind to GLUT2 promoter, whereas
SREBP-1c binding to GLUT2 promoter at high glucose
concentration was increased. We speculate that this dif-
ference in the binding of SREBP-1c to SRE of GLUT2
promoter could be due to 1) difference in the coregulators
recruiting SREBP-1c to SRE by insulin or glucose, or 2)
sequence specificity of GLUT2-SRE for SREBP-1c medi-
ated by insulin or glucose signaling. Mostly, studies on the
FIG. 3. Localization and characterizaion of SRE in the GLUT2 promoter. A: Schematic diagram of serial deletion constructs of GLUT2 promoter
reporter to localization of SRE in the GLUT2 promoter. The indicated numbers represent the number of nucleotides from the ATG codon. B: Effect
of SREBP-1c on the deletion constructs of GLUT2 promoter. The promoter activities were measured by cotransfecting 100 ng of SREBP-1c
expression or empty vectors into Alexander cell lines. The results were normalized by the amount of total protein of lysates, which were
determined by the Bradford method (21) and shown as the fold changes of luciferase activities compared with those of the control. Normalized
luciferase activities are shown as the means  SD of three independent experiments in triplicate. *P < 0.005 for the 166 vs. 57 deletion
construct. C: Electrophoretic mobility shift assay of GLUT2-SRE. The assay was performed with recombinant SREBP-1 protein in 4% (wt/vol)
nondenaturing polyacrylamide gel. Fifty thousand cpm (0.1 pmol) of 32P-labeled GLUT2 promoter fragments (101/67) containing putative SRE
were incubated with 20, 40, and 60 ng of recombinant SREBP-1 protein. D: Effect of mutation on the SREBP-1 binding to the putative GLUT2-SRE.
Site-directed mutation was introduced into the GLUT2-SRE sequence. SRE mutant was prepared by replacing TGA with aac. Wild-type and mutant
probes were labeled with [-32P]ATP, and EMSA was performed in 4% (wt/vol) nondenaturing polyacrylamide gel. For these experiments, 30 pmol
of each double-stranded oligonucleotide and 80 ng of SREBP-1 recombinant protein were used. Consensus sequence of SRE reported in the LDLR
promoter and mutant oligonucleotides were used as competitors. The DNA-protein complexes are indicated by an arrow. E: Effect of mutation
on the GLUT2-SRE on the SREBP-1c–driven promoter activity. A pSV-SREBP-1c expression vector was cotransfected with pmGT2d-389 or
pmGT2d-389m into Alexander cell lines. The luciferase activities were represented as fold changes compared with those of the control group.
Values are the means SD of three independent experiments in triplicate.
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phenotypic changes in SREBP-1c knockout mice have
been focused on the alteration in the lipid metabolism. On
a normal diet, mRNAs encoding enzymes of fatty acid and
triglyceride synthesis, including fatty acid synthase and
acetyl-CoA carboxylase, are shown to be reduced in the
liver of SREBP-1c–deficient mice (3). However, a compen-
satory increase in hepatic SREBP-2 mRNA, accompanied
by increased mRNA level for cholesterol biosynthetic
enzymes, was observed (38). Thus, these mice showed an
increase in hepatic cholesterol content. The SREBP-1–
deficient mice showed low level of plasma cholesterol
and triglycerides (3). At present, phenotypic changes in
SREBP-1c knockout mice with regard to carbohydrate
metabolism is not well studied. We assumed that in the
insulin-deficient or -resistant state, where SREBP-1c tran-
scription is low and gluconeogenesis is active in liver, the
glucose-induced SREBP-1c may play a role in transporting
glucose out of hepatocytes into blood, contributing to
hyperglycemia. Our studies may provide insight into the
understanding of a role of GLUT2 on deranged carbohy-
drate metabolism in type 2 diabetes.
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FIG. 4. Effect of a GLUT2-SRE mutation on the glucose-stimulated
GLUT2 promoter reporter activity. A: Effect of mutation in the putative
SRE on glucose-mediated GLUT2 promoter activity. A pmGT2d-389
(wild-type) or pmGT2d-389m (mutant-type) luciferase reporter vector
was transfected into mouse primary hepatocytes with the indicated
amount of glucose. *P < 0.05 for the wild-type 0 vs. 25 mmol/l glucose–
treated group; #P < 0.05 for the wild-type vs. mutant-type at 25 mmol/l
glucose, using paired t test. B: Effect of SREBP-1c DN on the glucose-
stimulated GLUT2 promoter activity. pmGT2d-1112 and SREBP-1c DN
were transfected into primary hepatocytes for 16 h, and 25 mmol/l
glucose was added to the culture media for 24 h. The luciferase
activities were represented as fold changes compared with those of the
control group. Values are the means  SD of three independent exper-
iments in triplicate. #P < 0.05 for the 25 mmol/l glucose vs. 25 mmol/l
glucose plus SREBP-1c DN, using paired t test.
FIG. 5. Glucose stimulation of GLUT2 gene expression. A and B:
Primary hepatocytes, which were fasted for 24 h, were maintained in
media containing the indicated concentration of glucose for 16 h.
GLUT2 mRNA and protein levels were quantified by Northern (A) and
Western (B) blot analyses. The blots are representative of two differ-
ent experiments. C: Effect of SREBP-1c DN on glucose-stimulated
GLUT2 expression. Adenovirus containing SREBP-1c or null adenovi-
rus (adeno-GFP) was transduced into primary hepatocytes at a titer of
5 pfu per cell for 2 h at 37°C. Cells were incubated in the presence (25
mmol/l) or absence of glucose for 24 h, and RNA was harvested from the
cells. The data were quantified as described in RESEARCH DESIGN AND
METHODS. The mRNA level was normalized to that of GAPDH. The
results are the means  SD of three independent experiments with
triplicate measurements. *P < 0.005 for Adeno-GFP vs. glucose; #P <
0.05 for the glucose vs. glucose plus SREBP-1c DN.
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